Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Non-Current Deffered Revenue (2017 - 2025)

Assembly Biosciences has reported Non-Current Deffered Revenue over the past 9 years, most recently at $1.7 million for Q3 2025.

  • Quarterly results put Non-Current Deffered Revenue at $1.7 million for Q3 2025, down 94.72% from a year ago — trailing twelve months through Sep 2025 was $1.7 million (down 94.72% YoY), and the annual figure for FY2024 was $35.4 million, down 36.12%.
  • Non-Current Deffered Revenue for Q3 2025 was $1.7 million at Assembly Biosciences, down from $13.0 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for ASMB hit a ceiling of $55.4 million in Q4 2023 and a floor of $1.7 million in Q3 2025.
  • Median Non-Current Deffered Revenue over the past 5 years was $2.7 million (2021), compared with a mean of $13.9 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 1926.31% in 2023 and later crashed 94.72% in 2025.
  • Assembly Biosciences' Non-Current Deffered Revenue stood at $2.7 million in 2021, then changed by 0.0% to $2.7 million in 2022, then soared by 1926.31% to $55.4 million in 2023, then crashed by 36.12% to $35.4 million in 2024, then crashed by 95.15% to $1.7 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $1.7 million (Q3 2025), $13.0 million (Q2 2025), and $22.8 million (Q1 2025) per Business Quant data.